Noor Jehanzeb 4

What Happened Noor Jehanzeb, Senior Vice President and Chief Strategy, Innovation & Business Development Officer at Zimmer Biomet (ZBH), was granted 1,857 restricted stock units (RSUs) on 2026-06-01. The Form 4 shows an acquisition price of $0 (this is an equity award, not a cash purchase). The RSUs are a derivative award that can convert into one share of common stock per unit upon vesting.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03 (filed within the normal reporting window).
• Grant: 1,857 RSUs; reported acquisition price: $0 (award/derivative).
• Vesting: vests annually over three years in one-third increments, commencing June 1, 2027 (per filing footnote).
• Shares owned after transaction: not specified in the provided filing summary.
• Footnotes: F1 — each RSU equals a contingent right to one share; F2 — three-year annual vesting schedule.
• No indication of a sale, exercise, or tax-withholding disposition in this filing.

Context RSU grants are a form of equity compensation; they do not involve an immediate cash purchase or sale and only convert into actual shares if and when they vest. This filing reflects a routine compensation award to an executive rather than an open-market buy or sale.